Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

ClinicalTrials.gov ID: NCT03737643

Public ClinicalTrials.gov record NCT03737643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Study identification

NCT ID
NCT03737643
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,407 participants

Conditions and interventions

Interventions

  • Bevacizumab Drug
  • Durvalumab Drug
  • Olaparib Drug
  • Placebo olaparib Drug
  • Durvalumab placebo Drug
  • Carboplatin+Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 3, 2019
Primary completion
Mar 16, 2025
Completion
Dec 22, 2026
Last update posted
Jul 6, 2026

2019 – 2026

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
Research Site Foothill Ranch California 92610
Research Site Los Angeles California 90095
Research Site Orange California 92868-3298
Research Site San Francisco California 94158
Research Site Tampa Florida 33612
Research Site Augusta Georgia 30912
Research Site Hinsdale Illinois 60521
Research Site Indianapolis Indiana 46202
Research Site Towson Maryland 21204
Research Site Detroit Michigan 48202
Research Site Springfield Missouri 65807
Research Site Middletown New Jersey 07748
Research Site Montvale New Jersey 07645
Research Site Albany New York 12208
Research Site New York New York 10065
Research Site Uniondale New York 11553
Research Site Durham North Carolina 27710
Research Site Cleveland Ohio 44195
Research Site Dayton Ohio 45429
Research Site Hilliard Ohio 43026
Research Site Tulsa Oklahoma 74134
Research Site Lancaster Pennsylvania 17601
Research Site Philadelphia Pennsylvania 19104
Research Site Philadelphia Pennsylvania 19107-5097
Research Site Pittsburgh Pennsylvania 15224
Research Site Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 188 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03737643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03737643 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →